https://www.selleckchem.com/pr....oducts/cct128930.htm
Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is indicated in the European Union and Japan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. The objective of this study was to evaluate the safety of baricitinib 2 mg in the AD clinical program. Six double-blind, randomized, placebo-controlled studies, and two long-term extension studies were summarized in two datasets. Placebo comparison was based on six 16-week studies with baricitinib 2 mg. All-bari-2
Like
Comment
Share
